Recently, it has been proposed that EZH2 can influence lymphocyte subpopulation differentiation and function to reshape the TME, and thus inhibition of EZH2 may be a novel strategy to improve anti-tumor immunity in certain cancers (112–114). The gene discussed is EZH2; the disease is cancer.